Venquis Therapeutics
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Venquis Therapeutics
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Chemically Targeted Protein Degradation
Transformational Chemical-Biology Platform: CIPD
Venquis Therapeutics has developed a small molecule monovalent degrader discovery platform named CIPD: Chemically Induced Protein Degrader
Mutant-selective Targeting
Our initial compounds target clinically relevant proteins in a mutant-selective fashion: degrading the driver-mutant proteins while sparing their corresponding endogenous wild-type proteins
Oncology and Beyond
Oncology and Beyond
This is a powerful approach for addressing oncology and other classes of target proteins
Our Approach
Direct Protein Degraders
We discover and develop mechanistically differentiated targeted small molecule direct protein degraders. These are not molecular glues or PROTACs. These directly bind the Protein Of Interest, which is then targeted for cellular degradation
Screening and Rational Design
We developed a focused chemical library screening platform to identify novel direct protein degraders
We simultaneously use structure-based analog design from known chemical binders to create new direct degraders
Our Pipeline
Our initial programs and targets are of high consequence
- Venquis has identified novel isoform-selective degraders of cancer driver mutant PI3Kalpha, while sparing wild-type PI3Kalpha
- Similarly, early KRAS-G12D selective degraders maintain wild-type KRAS sparing